Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Luciana, Molinero"'
Autor:
Smruthy Sivakumar, Dexter X. Jin, Hanna Tukachinsky, Karthikeyan Murugesan, Kimberly McGregor, Natalie Danziger, Dean Pavlick, Ole Gjoerup, Jeffrey S. Ross, Robert Harmon, Jon Chung, Brennan Decker, Lucas Dennis, Garrett M. Frampton, Luciana Molinero, Steffi Oesterreich, Jeffrey M. Venstrom, Geoffrey R. Oxnard, Priti S. Hegde, Ethan S. Sokol
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Liquid biopsies could be valuable tools to monitor breast cancer progression and evolution. Here, the authors investigate genomic profiling of tissue and liquid biopsies in a large cohort of patients with breast cancer during the course of therapy to
Externí odkaz:
https://doaj.org/article/b3aeff304c474e6c83d5647b3e086870
Autor:
Romain Banchereau, Ning Leng, Oliver Zill, Ethan Sokol, Gengbo Liu, Dean Pavlick, Sophia Maund, Li-Fen Liu, Edward Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe June Assaf, Daniel Bower, Namrata Patil, Mark McCleland, David Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti Hegde, Thomas Powles
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response t
Externí odkaz:
https://doaj.org/article/ae29efdfced64f11b4172bdb2e1a8bde
Autor:
Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study d
Externí odkaz:
https://doaj.org/article/dd95d67f18f340099d4709fdb5d1dae3
Autor:
Charles N. Landen, Luciana Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Kathleen N. Moore, Cagatay Taskiran, Michael Bookman, Kristina Lindemann, Charles Anderson, Regina Berger, Tashanna Myers, Mario Beiner, Thomas Reid, Els Van Nieuwenhuysen, Andrew Green, Aikou Okamoto, Carol Aghajanian, Premal H. Thaker, Stephanie V. Blank, Victor K. Khor, Ching-Wei Chang, Yvonne G. Lin, Sandro Pignata
Publikováno v:
Clinical Cancer Research. 29:1698-1707
Purpose: To explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial. Patients and Methods: Patients with newly diagnosed ova
Autor:
Sandro Pignata, Yvonne G. Lin, Ching-Wei Chang, Victor K. Khor, Stephanie V. Blank, Premal H. Thaker, Carol Aghajanian, Aikou Okamoto, Andrew Green, Els Van Nieuwenhuysen, Thomas Reid, Mario Beiner, Tashanna Myers, Regina Berger, Charles Anderson, Kristina Lindemann, Michael Bookman, Cagatay Taskiran, Kathleen N. Moore, Austin Miller, Jalid Sehouli, Habib Hamidi, Luciana Molinero, Charles N. Landen
PFS by treatment arm according to TMB status (stratified by treatment approach, disease stage, and ECOG PS). A, TMB-low population. B, TMB-high population. CPB, paclitaxel, carboplatin, and bevacizumab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab8226269a076ceaa25dfedd6f80336
https://doi.org/10.1158/1078-0432.22725021
https://doi.org/10.1158/1078-0432.22725021
Autor:
Sandro Pignata, Yvonne G. Lin, Ching-Wei Chang, Victor K. Khor, Stephanie V. Blank, Premal H. Thaker, Carol Aghajanian, Aikou Okamoto, Andrew Green, Els Van Nieuwenhuysen, Thomas Reid, Mario Beiner, Tashanna Myers, Regina Berger, Charles Anderson, Kristina Lindemann, Michael Bookman, Cagatay Taskiran, Kathleen N. Moore, Austin Miller, Jalid Sehouli, Habib Hamidi, Luciana Molinero, Charles N. Landen
Purpose:To explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial.Patients and Methods:Patients with newly diagnosed ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9312f31f3a27a5e8188557bdcc517b4
https://doi.org/10.1158/1078-0432.c.6533182
https://doi.org/10.1158/1078-0432.c.6533182
Autor:
Xiao Li, Jeffrey Eastham, Jennifer M. Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Nabet, Namrata Patil, Luciana Molinero, Steve Chui, Maureen Peterson, Shari Lau, Linda Rangell, Yannick Waumans, Mark Kockx, Darya Orlova, Hartmut Koeppen
BackgroundCancer immunotherapy has transformed the clinical approach to patients with malignancies as profound benefits can be seen in a subset of patients. To identify this subset, biomarker analyses increasingly focus on phenotypic and functional e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9a0bf9b33176a2dd1f8dab2f6464a00
https://doi.org/10.1101/2023.04.03.535467
https://doi.org/10.1101/2023.04.03.535467
Autor:
Antoni Ribas, Yibing Yan, Lukas Amler, Ilsung Chang, Huibin Yue, Luciana Molinero, Priti S. Hegde, Isabelle Rooney, Ivor Caro, Stephen D. Hurst, Mark Kockx, Luc Andries, Jeffrey Sosman, Paolo A. Ascierto, James Larkin, Brigitte Dréno, Grant A. McArthur, Matthew J. Wongchenko
Supplementary Figure S3. Association of the cell cycle/immune signature with B, lactate dehydrogenase levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea914eb36a0663bbdbd8e1f2b2f8083
https://doi.org/10.1158/1078-0432.22466237.v1
https://doi.org/10.1158/1078-0432.22466237.v1
Autor:
Antoni Ribas, Yibing Yan, Lukas Amler, Ilsung Chang, Huibin Yue, Luciana Molinero, Priti S. Hegde, Isabelle Rooney, Ivor Caro, Stephen D. Hurst, Mark Kockx, Luc Andries, Jeffrey Sosman, Paolo A. Ascierto, James Larkin, Brigitte Dréno, Grant A. McArthur, Matthew J. Wongchenko
Purpose: The association of tumor gene expression profiles with progression-free survival (PFS) outcomes in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib was evaluated.Experimental Design: G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecddf22667cc71d93b7b2572ce9e18d
https://doi.org/10.1158/1078-0432.c.6526268
https://doi.org/10.1158/1078-0432.c.6526268
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Purpose:Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10746515c079c17f9a6ccbb5603f4804
https://doi.org/10.1158/1078-0432.c.6527925.v1
https://doi.org/10.1158/1078-0432.c.6527925.v1